Sirolimus-eluting stents versus paclitaxel-eluting stents in patients with chronic renal insufficiency

Journal of Interventional Cardiology

Volumn 23, Issue 1, 2010, Pages 33-39

  Syed, Asmir I ^a   Ben Dor, Itsik ^a   Collins, Sara D ^a   Gonzalez, Manuel A ^a   Gaglia Jr , Michael A ^a   Torguson, Rebecca ^a   Satler, Lowell F ^a   Suddath, William O ^a   Pichard, Augusto D ^a   Lindsay, Joseph ^a   Waksman, Ron ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; RAPAMYCIN;

AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVASCULARIZATION; STENT THROMBOSIS; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; FEMALE; GLOMERULAR FILTRATION RATE; HOSPITAL MORTALITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; RISK FACTORS; SIROLIMUS; TREATMENT OUTCOME; UNITED STATES;

EID: 76749142034     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2009.00524.x     Document Type: Article

References (22)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998 32 : S112 S119.
2. Halkin A, Mehran R, Casey CW, et al. Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: Results from the TAXUS-IV Trial. Am Heart J 2005 150 : 1163 1170.
3. Jeong YH, Hong MK, Lee CW, et al. Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation. Int J Cardiol 2008 125 : 36 40.
4. Das P, Moliterno DJ, Charnigo R, et al. Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous coronary revascularization. J Invasive Cardiol 2006 18 : 405 408.
5. Halkin A, Selzer F, Marroquin O, et al. Clinical outcomes following percutaneous coronary intervention with drug-eluting vs. bare-metal stents in dialysis patients. J Invasive Cardiol 2006 18 : 577 583.
6. Hassani SE, Chu WW, Wolfram RM, et al. Clinical outcomes after percutaneous coronary intervention with drug-eluting stents in dialysis patients. J Invasive Cardiol 2006 18 : 273 277.
7. Kari JA, Donald AE, Vallance DT, et al. Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int 1997 52 : 468 472.
8. Blacher J, London GM, Safar ME, et al. Influence of age and end-stage renal disease on the stiffness of carotid wall material in hypertension. J Hypertens 1999 17 : 237 244.
9. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000 356 : 147 152.
10. Zoungas S, Ristevski S, Lightfoot P, et al. Carotid artery intima-medial thickness is increased in chronic renal failure. Clin Exp Pharm Physiol 2000 27 : 639 641.
11. Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001 : 2131 2138.
12. Hörl WH. The clinical consequences of secondary hyperparathyroidism: Focus on clinical outcomes. Nephrol Dial Transplant 2004 19 (Suppl 5 V2 V8.
13. Costa- Hong V, Jorgetti V, Gowdak LH, et al. Parathyroidectomy reduces cardiovascular events and mortality in renal hyperparathyroidism. Surgery 2007 142 : 699 703.
14. Rubenstein MH, Harrell LC, Sheynberg BV, et al. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation 2000 102 : 2966 2972.
15. Nikolsky E, Mehran R, Turcot D, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol 2004 94 : 300 305.
16. Zhu ZB, Zhang RY, Zhang Q, et al. Moderate-severe renal insufficiency is a risk factor for sirolimus-eluting stent thrombosis. The RIFT study. Cardiology 2009 112 : 191 199.
17. Ishio N, Kobayashi Y, Takebayashi H, et al. Impact of drug-eluting stents on clinical and angiographic outcomes in dialysis patients. Circ J 2000 71 : 1525 1529.
18. Mishkel GJ, Varghese JJ, Moore AL, et al. Short and long-term clinical outcomes of coronary drug eluting stent recipients presenting with chronic renal disease. J Invasive Cardiol 2007 19 : 331 337.
19. Mason NA, Bailie GR, Satayathum S, et al. HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 2005 45 : 119 126.
20. Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009 360 : 1395 1407.
21. Rahmanian PB, Adams DH, Castillo JG, et al. Early and late outcome of cardiac surgery in dialysis-dependent patients: Single-center experience with 245 consecutive patients. J Thorac Cardiovasc Surg 2008 135 : 915 922.
22. Shaw JA, Adrinaopoulos N, Duffy S, et al. Renal impairment is an independent predictor of adverse events post coronary intervention in patients with and without drug-eluting stents. Cardiovasc Revasc Med 2008 9 218 223.